EPICS: Global Perspectives in Lung Cancer in 2022 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of ESMO and WCLC 2022 regarding lung cancer treatment.
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
Faculty Members
Marina Chiara Garassino, MD
University of Chicago, IL, USA
Antoinette J. Wozniak, MD
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
David Spigel, MD
Sarah Cannon Research Institute, Nashville, TN, USA
Natasha Leighl, MD
University of Toronto, ON, Canada
Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
Egbert Smit, MD, PhD
The Netherlands Cancer Institute, Amsterdam
Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland
Luis Paz-Ares, MD, PhD
Hospital Universitario 12 Octubre, Madrid, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Perioperative Immunotherapy in Early-Stage NSCLC
- SCLC, Mesothelioma, Second-Line NSCLC, and Beyond: Old and New Data
- Frontline Immunotherapy in Metastatic NSCLC
- Immunotherapy in Unresectable Stage III NSCLC
- EGFR (Common Mutations): Resectable and Metastatic
- EGFR (Less Common Mutations, Including Exon 20 Insertions)
- Oncogenic Drivers: Mutations
- Oncogenic Drivers: Fusions
